PROTECT Trial: Pegloticase for Uncontrolled Gout in Kidney Transplant Recipients
Early findings from the PROTECT trial,1 presented at the 2022 American Society of Nephrology’s...
Read More
Meeting Coverage
Health and Safety Protocols
Key Protocols: Vaccination will be required for all in-person meeting attendees. ASH is offering complimentary* medical evacuation and quarantine support coverage. Proof of a negative COVID-19 test is not required for in-person...
Read MoreASH Foundation Run & Walk
The ASH Foundation Run & Walk will start and finish on Convention Center Boulevard and Julia Street, head toward the Riverwalk near the Audubon Aquarium of the Americas, and go through Woldenberg Park. Schedule: 7:00 a.m....
Read MoreFriday Satellite Symposia
FSS are industry-supported, CME-certified symposia. These sessions are not part of the official ASH annual meeting program and are planned solely by the sponsoring company. Morning Topics: A Thread To Pull: Unraveling The...
Read MoreFriday Satellite Symposia
FSS are industry-supported, CME-certified symposia. These sessions are not part of the official ASH annual meeting program and are planned solely by the sponsoring company. Morning Topics: A Thread To Pull: Unraveling The...
Read MoreASH Foundation Run & Walk
The ASH Foundation Run & Walk will start and finish on Convention Center Boulevard and Julia Street, head toward the Riverwalk near the Audubon Aquarium of the Americas, and go through Woldenberg Park. Schedule: 7:00 a.m....
Read MoreHealth and Safety Protocols
Key Protocols: Vaccination will be required for all in-person meeting attendees. ASH is offering complimentary* medical evacuation and quarantine support coverage. Proof of a negative COVID-19 test is not required for in-person...
Read MoreASH Schedule At A Glance
Friday, December 9th 7:00 a.m.– 6:00 p.m. Registration open (for in-person participants) 7:00 a.m. – 10:00 a.m. Friday Satellite Symposia 9:00 a.m. – 12:00 Training Program Directors’ Workshop 11:00 a.m. – 2:00 p.m. Friday...
Read More
Aggressive Serum Urate Lowering Meets Goals in Gout
At the 2022 American College of Rheumatology, ACR Convergence meeting, Dr. Sarah Black, a...
Read MoreGout Has Causal Role in the Onset of Hypertension
Past observational studies have shown a link between hypertension and gout, but whether a causal relationship existed was unclear, according to Chang-Fu Kuo, MD, PhD. For a study published in Arthritis Research & Therapy,...
Read More
Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Secondary Hematological Malignancies
Patients with aggressive hematological malignancies and second primary malignancies can develop in...
Read More
Initial Treatment for CLL/ SLL: Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab
For a study, researchers sought to determine if ibrutinib combined with fludarabine,...
Read More
Ibrutinib Treatment for CLL/SLL: Overall and Subgroup Results from the Third Interim Analysis of FIRE
FIRE is a noninterventional, multicenter observational trial of patients in France receiving...
Read More
CLL/SLL Patients: Real-World Outcomes with First-Line Ibrutinib (Ibr) VS. Chemoimmunotherapy (CIT)
With the development of cutting-edge drugs like Ibr, the treatment landscape for CLL/SLL has...
Read More
African American Patients with Diffuse Large B-Cell Lymphoma: Predictors of Inferior Survival
African American (AA) patients with diffuse large b-cell lymphoma (DLBCL) experience differences...
Read More
Neutrophil-to-Lymphocyte Ratio in Gout Suggests Sustained Post-Flare Inflammation
At the 2022 American College of Rheumatology Convergence meeting, Michael Pillinger, MD, presented...
Read More
Patients With IBS With Diarrhea Experience Significant Burden on HRQOL
For patients with irritable bowel syndrome with diarrhea (IBS-D), symptoms such as abdominal pain...
Read MoreDiffuse Large B-Cell Lymphoma Patients: Impact of Circulating Lymphoma at Diagnosis on Outcomes
The most prevalent B-cell non-Hodgkin lymphoma is diffuse large B-cell lymphoma (DLBCL). Various prognostic factors were known, including the revised international prognostic index (R-IPI), MYC/BCL2 overexpression by IHC,...
Read MorePatients With IBS With Diarrhea Experience Significant Burden on HRQOL
Patients with IBS-D had significantly higher percentages of moderate to severe anxiety and depression and considerably lower HRQOL versus controls. For patients with irritable bowel syndrome with diarrhea (IBS-D), symptoms such...
Read More
Predictor of Response to Loncastuximab Tesirine: Expression by IHC
A number of CD19-targeted medicines, such as chimeric antigen receptor T-cell therapy (CAR-T),...
Read More